Cholestagel

Quick links to important sections

Cholestagel

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cholestagel

Property Description
Active ingredient Colesevelam Hydrochloride
Form Film-coated tablets, Powder for oral suspension
Pharmacological class Bile Acid Sequestrant (BAS)
Common purpose Cholesterol-lowering agent
Origin Synthetic, non-systemic polymer

What Type of Medicine is Cholestagel?

Cholestagel is a prescription medication whose active substance is Colesevelam Hydrochloride, belonging to the pharmacological class of Bile Acid Sequestrants (BAS). It is an antilipemic (lipid-lowering) agent, structurally defined as a synthetic, non-systemic polymer designed for oral administration. The drug is characterized by its targeted action, meaning it functions exclusively within the digestive tract and is not absorbed into the body's circulation. This unique property distinguishes it from drugs that act systemically, such as statins.

Colesevelam effectively binds bile acids, preventing their reabsorption and recycling, a fundamental property of this drug class. This means the drug works by blocking a specific pathway in your gut to help manage your cholesterol.


Composition and General Purpose

The medicine contains Colesevelam Hydrochloride as its single active ingredient and is supplied primarily as film-coated tablets. Colesevelam is a high-capacity, allylamine derivative polymer, which represents a modern iteration within the BAS class. The primary function of this drug class is to help reduce elevated blood levels of Low-Density Lipoprotein cholesterol (LDL-C). This specific BAS is effective in reducing LDL-C, often utilized as part of a regimen for patients with primary hypercholesterolemia.

The increased elimination of bile acids forces the liver to convert its stored cholesterol into new bile acids, resulting in the efficient removal of LDL-C from the bloodstream. This action is central to its general purpose of supporting cardiovascular health by addressing a key factor in high cholesterol.

Regulatory References

  1. EMA EPAR: Cholestagel
  2. MedlinePlus: Colesevelam Drug Information

What side effects are possible with Cholestagel?

Possible Side Effects and Safety Information

The safety profile of Colesevelam Hydrochloride (Cholestagel) is primarily characterized by events affecting the Gastrointestinal System, reflecting its non-systemic mechanism as a Bile Acid Sequestrant. The officially documented adverse reactions are categorized by frequency, as defined in regulatory sources like the FDA and EMA.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common (More than 1 in 10) Constipation, Flatulence
Common (Up to 1 in 10) Nausea, Abdominal pain, Dyspepsia (Indigestion), Headache, Back pain, Raised triglyceride levels, Vomiting, Diarrhea
Uncommon (Up to 1 in 100) Difficulty in swallowing (Dysphagia), Increased Serum Transaminases (Liver enzymes)

Clinically Significant and Serious Reactions

Regulatory documents list certain serious adverse reactions, which may occur rarely. These include Gastrointestinal Obstruction (such as Intestinal or Esophageal obstruction and Fecal impaction) and Acute Pancreatitis. The official labeling defines these events as clinically important safety risks.


Regulatory Safety Constraints

The medicine is contraindicated (should not be used) in patients with serum triglyceride concentrations greater than 500 mg/dL and in those with a history of bowel obstruction or hypertriglyceridemia-induced pancreatitis. Official safety notes indicate that Colesevelam may reduce the absorption of fat-soluble vitamins (Vitamins A, D, E, and K), a consideration for patients on long-term treatment. Caution is also specifically noted for individuals with pre-existing gastrointestinal motility disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

Cholestagel (Colesevelam Hydrochloride) is a non-systemic polymer, and its overdose profile primarily relates to severe, localized effects in the gastrointestinal tract. The official regulatory description notes that overdose may result in the exacerbation of documented conditions such as bowel obstruction, esophageal obstruction, and fecal impaction. These manifestations are mechanical in nature, stemming from the accumulation of the non-absorbed substance.

A serious metabolic complication associated with the drug is acute pancreatitis, which may occur secondary to severe hypertriglyceridemia. If symptoms of this condition arise (severe abdominal pain with or without nausea and vomiting), official guidance mandates that patients discontinue the drug and seek prompt medical attention.

General emergency actions are required for severe systemic events. Individuals must contact a Poison Control center or call emergency services (911) immediately if signs such as collapse, seizure, or trouble breathing are observed. Treatment is symptomatic and supportive, as regulatory labeling confirms that no specific antidote is known for Colesevelam. Continuous monitoring of triglyceride levels is a required component of management due to the associated metabolic risk.

Therapeutic Uses of Cholestagel

What Cholestagel Treats: Main Uses and Benefits

Cholestagel is generally used in situations involving symptoms related to systemic imbalance and is applied across therapeutic domains where additional support for symptom management is needed. The medication is considered relevant for the management of major areas, including: elevated LDL cholesterol (including in patients with Heterozygous Familial Hypercholesterolemia, or HeFH), and may be part of symptomatic management for Type 2 Diabetes Mellitus.


Core Management of Elevated LDL Cholesterol

This domain is commonly used to help with addressing high levels of Low-Density Lipoprotein Cholesterol (LDL-C), a central biomarker of cardiovascular risk. This therapeutic approach plays a role in managing functional stability and may assist with long-term cardiovascular health.


Dual Support for High Cholesterol and Type 2 Diabetes

The agent is commonly applied in clinical scenarios when supportive symptomatic management is needed, such as when patients require additive therapy to reach critical lipid goals, or when they are statin-intolerant and are seeking an additional option for cholesterol-lowering.


Strategic Use for Therapeutic Gaps

When used in patients with Type 2 Diabetes, the dual benefit supports patients during episodes of heightened discomfort by easing the overall symptom load associated with these two chronic metabolic conditions. This application may support efforts to reach critical lipid goals, assisting with maintaining functional stability.

Quick Fact: Management for Risk Factors

Cholestagel is relevant for managing two distinct groups of symptoms related to systemic imbalance: high LDL-C and unstable HbA1c levels, which may assist with maintaining functional stability associated with chronic disease.

Eligibility and Restrictions for Use

Eligibility Scope

The official eligibility profile for Cholestagel (Colesevelam) is defined by age, metabolic status, and gastrointestinal health.

Classification Population or Condition
Allowed Use Adults for hyperlipidemia and Type 2 Diabetes Mellitus. Boys and postmenarchal girls aged 10–17 with Heterozygous Familial Hypercholesterolemia (HeFH).
Contraindicated Serum Triglycerides (TG) > 500 mg/dL, History of hypertriglyceridemia-induced pancreatitis, or History of bowel obstruction.

Eligibility-Related Restrictions

Use of the medicine is not recommended for patients at risk of bowel obstruction, such as those with gastrointestinal motility disorders or a history of major GI tract surgery. Patients with TG levels > 300 mg/dL require special caution and monitoring.

Regulatory documents state that use is not established in children younger than 10 years of age, or for specific dyslipidemia types (Fredrickson Type I, III, IV, V). The medicine must not be used for treating Type 1 diabetes or diabetic ketoacidosis.

As the drug is not systemically absorbed, it is not expected to distribute into breast milk; however, caution is noted regarding its potential to affect fat-soluble vitamin levels during pregnancy.

What should I know about interactions with other medicines?

Cholestagel (Colesevelam) exhibits an official interaction profile defined primarily by its function as a non-systemic bile acid sequestrant. The mechanistic basis of its most frequent interactions is reduced gastrointestinal absorption of co-administered medicinal products, which results in a decreased systemic exposure of the interacting drug.

Interaction-Related Restrictions and Constraints

Official regulatory documents specify several agents that must be administered at least four hours prior to Colesevelam to minimize the risk of reduced exposure. These agents include: Thyroid Hormone Replacement Therapy (e.g., Levothyroxine), Anticonvulsants (e.g., Phenytoin), Immunosuppressants (e.g., Cyclosporine), and Oral Contraceptives (containing Ethinyl Estradiol and Norethindrone). This timing rule also applies to Sulfonylureas (e.g., Glipizide), the anticoagulant Warfarin, and the antihypertensive agent Olmesartan Medoxomil.

Conversely, co-administration with Colesevelam is officially documented to result in an increase in the systemic exposure of Metformin Extended-Release (ER).

Population-Specific Constraint

Patients receiving concomitant Warfarin require frequent monitoring of their International Normalized Ratio (INR) during the initiation of Colesevelam and periodically thereafter. This necessity stems from the documented potential for reduced absorption of Vitamin K, an interaction effect associated with bile acid sequestrants. Furthermore, Colesevelam may reduce the absorption of fat-soluble vitamins (A, D, E, K), leading to a four-hour separation requirement for oral vitamin supplements.

Mechanism of Action

Disruption of Bile Acid Recycling

Cholestagel (Colesevelam) acts entirely within the digestive tract, utilizing specific feedback mechanisms to produce physiological changes. The overall mechanism is non-systemic, as the drug is not absorbed into the body's circulation. The non-absorbed, polymeric drug physically binds to bile acids in the intestinal lumen, preventing their reabsorption and forcing their elimination via feces. This interruption of the enterohepatic circulation is the initial molecular event that creates a functional demand in the liver.


Hepatic Compensation and Pathway Modulation

The liver responds to the loss of bile acids by increasing the activity of CYP7A1 to convert stored cholesterol into new bile acids. To fulfill this demand, the liver increases the number of LDL Receptors on its surface. This compensatory mechanism results in enhanced clearance of LDL-C particles from the systemic circulation, producing a change in circulating plasma lipid levels.

In addition, the localized binding of bile acids modulates signaling through intestinal receptors, hypothesized to include TGR5. This interaction supports the enhanced secretion of incretin hormones, such as GLP-1, which indirectly influences the pathways governing glucose metabolism.

Dosage and Administration Information

How to Use Cholestagel

Cholestagel (Colesevelam Hydrochloride) is administered exclusively via the oral route and is structured around a non-systemic use protocol that requires strict adherence to dosing and timing conditions. The medicine is available as 625 mg film-coated tablets and as a 3.75 gram powder for oral suspension.


Dosing and Frequency Guidelines

The standard adult total daily dose for primary hyperlipidemia and Type 2 Diabetes Mellitus is 3.75 grams. This dose can be taken either once daily (six 625 mg tablets or one 3.75 g packet) or as a divided dose twice per day (three tablets or one 1.875 g packet, where available). This set daily amount represents the maintenance dose, and lipid levels are typically assessed within four to six weeks following initiation to monitor the treatment response.


Administration Requirements

The correct use of Colesevelam is governed by specific instructions related to ingestion and timing:

  • Food and Liquid: The medication must always be taken with a meal and liquid.
  • Tablet Integrity: Tablets must be swallowed whole and must not be crushed, cut, or chewed.
  • Preparation: The oral suspension powder must be mixed with 8 ounces (1 cup) of water, juice, or a diet soft drink and consumed immediately; it is not to be taken in its dry powder form.
  • Timing with Other Drugs: Other medications, particularly those where absorption may be affected, should be administered at least 4 hours prior to taking Colesevelam to minimize potential binding interference.

Population-Specific Use

For pediatric patients (boys and postmenarchal girls 10–17 years old) with Heterozygous Familial Hypercholesterolemia (HeFH), the recommended total daily dose is also 3.75 grams. Due to the size of the tablets, the oral suspension is generally recommended for this age group.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cholestagel

The clinical evaluation of Colesevelam Hydrochloride (Cholestagel) has primarily focused on research exploring conditions such as high cholesterol and elevated blood sugar levels in Type 2 Diabetes. The research base consists mainly of randomized controlled trials (RCTs), which research explores by examining changes in specific biomarkers.


Evidence for Use in Lowering Elevated LDL Cholesterol

The research base exploring the effects on cholesterol biomarkers relies on multiple short-term randomized controlled trials and subsequent medium-term extension studies. Researchers evaluated the medicine in studies both as a sole therapy and as an add-on to other lipid-modifying agents, such as statins. The primary outcome measured in these trials was the change in Low-Density Lipoprotein Cholesterol (LDL-C) levels. Study populations included adults with primary hyperlipidemia and pediatric patients (ages 10 to 17) with Heterozygous Familial Hypercholesterolemia (HeFH).

What the Studies Reported

Studies reported patterns where measured LDL-C levels evolved across the observed populations. These findings describe changes in the lipid profile during the study period, which typically lasted between 6 weeks and up to a year. Findings described patterns of change in Triglyceride (TG) levels, a finding noted in the reported data across trials.

What Remains Uncertain

A primary research limitation is that the clinical trials have not determined the drug's effect on major long-term cardiovascular outcomes, such as the rate of heart attacks or strokes. Research so far focuses on changes in lipid biomarkers, and there is limited information regarding the maintenance of these changes over many years.


Evidence for Use in Type 2 Diabetes Mellitus

The research exploring Colesevelam in Type 2 Diabetes focuses on its evaluation as an add-on therapy by examining blood sugar markers. The evidence base primarily consists of intermediate-term randomized controlled trials.

What Researchers Studied

Studies were conducted in adults with Type 2 Diabetes who had inadequate blood sugar control despite having been stabilized on existing medications. Research examined changes in the long-term blood sugar biomarker, Glycated Hemoglobin (HbA1c), and Fasting Plasma Glucose (FPG). Trials also explored whether the medicine was associated with reaching defined targets for both blood sugar and cholesterol.

What Remains Uncertain

Long-term effects are not fully established regarding the maintenance or durability of the changes measured. Furthermore, the effect on long-term clinical outcomes, specifically regarding cardiovascular events in patients with T2DM, has not been determined. Data for Type 1 diabetes patients remain insufficient.

Key Studies & References Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study

Frequently Asked Questions (FAQ)

Common questions about Cholestagel (FAQ)


Q: Is Cholestagel the same as other medicines for high cholesterol?

Cholestagel belongs to a class of medicines called Bile Acid Sequestrants (BAS). According to official product information, this means it works locally in your gut rather than being absorbed into your bloodstream. This mechanism is different from systemic drugs, such as statins, which have a different action inside the body.


Q: Does Cholestagel treat high cholesterol, or just help manage it?

Official documentation states that this medicine is indicated for reducing elevated LDL cholesterol levels in the blood. It is designed to be utilized as part of a long-term plan, known as a management regimen, that also requires diet and exercise.


Q: How quickly does Cholestagel start to work in the body?

The primary action of the medicine, which is binding bile acids, begins immediately after you take it. However, the resulting effect on your lipid (fat) levels in the blood is typically assessed and monitored by healthcare professionals within four to six weeks of starting treatment.


Q: What are the most common things Cholestagel should not be taken with?

Regulatory documents state that Cholestagel has the potential to reduce the absorption of certain other medicines taken at the same time. Official documents state the requirement that certain medicines, including thyroid hormone replacements or certain oral contraceptives, should be administered at least four hours prior to taking Cholestagel.


Q: How does Cholestagel lower cholesterol differently than a statin?

Cholestagel works by physically binding to bile acids in your intestine, preventing their recycling and causing them to be eliminated. This process forces your liver to use its stored cholesterol to make new bile acids, resulting in the removal of cholesterol from your bloodstream. Statins work differently by reducing the amount of cholesterol the liver produces internally.


Q: Can people with liver problems use Cholestagel?

Official information states that the medicine is generally not absorbed systemically in the body. However, caution is advised for people with elevated triglyceride levels (a type of fat in the blood). Clinical trials also noted an uncommon occurrence of increased liver enzymes (serum transaminases) as a side effect.


Q: Do I need to change my diet while taking Cholestagel?

Regulatory information states that the medicine should be used in conjunction with an appropriate diet recommended by a health professional for managing cholesterol or blood sugar. Furthermore, official administration instructions state the requirement that the medicine is administered with a meal and liquid.


Q: Is Cholestagel safe to use during pregnancy, according to official sources?

According to official documents, the use of Cholestagel during pregnancy has not been formally studied. The medicine is not absorbed into the bloodstream, but caution is noted regarding its potential to reduce the absorption of fat-soluble vitamins (A, D, E, K) in pregnant individuals.


Q: What types of food or drink interactions are mentioned for Cholestagel?

Official regulatory texts contain the administration requirement that the medicine is administered with a meal and liquid to ensure proper use. No specific types of foods or drinks are listed as being formally contraindicated or requiring avoidance while taking the medicine.


Q: Can taking Cholestagel affect the results of blood tests?

The safety profile based on clinical trials includes documented changes in the results of certain laboratory tests. These changes include a common finding of raised triglyceride levels and an uncommon finding of increased serum transaminases (a measure of liver enzymes).


Q: What does 'adjunctive therapy' mean in the context of Cholestagel?

Adjunctive therapy is the term used in official documentation to describe the medicine’s role as an addition to other established treatments or lifestyle changes. This indicates that it is often intended to be used as an add-on to therapies like statins, or alongside diet and exercise, to help achieve therapeutic targets.


Q: What happens if I forget to take my Cholestagel dose sometimes?

Official patient labeling often provides general guidance regarding missed doses. This information typically advises that taking the next scheduled dose and avoiding taking two doses at once is the guidance provided for a missed dose.


Q: Are there any common long-term side effects of taking Cholestagel?

The documented adverse reactions, such as constipation and flatulence, are classified by frequency based on clinical trials, which typically lasted up to one year. Official research currently notes that the effect on long-term cardiovascular outcomes beyond the trial period has not been determined.


Q: Are there special considerations for older adults taking Cholestagel?

According to regulatory documents, the official dosing guidelines for the medicine do not specify a separate dose adjustment for older adults. This indicates that the standard adult dosing and administration instructions are applicable to geriatric patients.


Q: Why do official documents mention that Cholestagel is for primary hypercholesterolemia?

Primary hypercholesterolemia refers to high cholesterol that is not caused by an underlying disease or secondary medical condition. This term is used because it defines the specific condition for which the drug’s efficacy was originally established and subsequently approved by regulatory bodies.


Q: Does Cholestagel need to be taken at a specific time of day?

Official administration instructions state that the total daily dose can be taken either once daily or as a divided dose twice per day. Regulatory information does not specify a preferred or required time of day for administration (such as morning versus evening).


Q: Is it possible for Cholestagel to stop working after a while?

The medicine is a non-systemic polymer that works via a chemical and physical process of binding bile acids in the gut. The official mechanism of action does not describe a pathway for the body to develop a biological tolerance to its effect over time.


Q: Are there documented cases of allergic reactions to Cholestagel?

Official patient information leaflets typically describe the signs of a serious allergic reaction, such as swelling of the face, tongue, or throat, as conditions that warrant immediate attention.


Q: Why is it important to take Cholestagel exactly as directed, even if I feel fine?

The therapeutic goal of lowering LDL cholesterol levels does not produce immediate physical sensations because the medicine acts only locally in the gut. Taking it as directed ensures the necessary continuous binding action in the digestive tract is maintained to achieve the desired effect.


Q: Does Cholestagel contain any common allergens like gluten or lactose?

Official documents, such as the Summary of Product Characteristics, list all inactive ingredients, known as excipients. Information about the presence or absence of specific common allergens like lactose or gluten is typically provided in this section of the regulatory documents.


Q: Can Cholestagel affect fertility in men or women, based on official information?

Official regulatory information includes a section on fertility. Standard documentation often states that studies have not been conducted in human subjects to determine the direct effect of the medicine on fertility in men or women.


Q: Do different regulatory bodies have different approved uses for Cholestagel?

Official texts for major regulatory bodies, such as the U.S. FDA and the European Medicines Agency (EMA), list similar core approved uses for the medicine. These indications include the use in Primary hypercholesterolemia and use as an add-on therapy for Type 2 diabetes.

How should Cholestagel be stored and disposed of?

How to Store and Dispose of Cholestagel?

Cholestagel (colesevelam hydrochloride) tablets must be stored according to specific regulatory requirements to maintain product stability and ensure safety.


Official Storage Requirements

  • Temperature and Protection: Store at room temperature (20 C to 25 C). The product must be protected from moisture, excess heat, and direct light, and must not be frozen.
  • Container and Stability: The bottle must be kept tightly closed in the original container. Once the container is opened, the tablets must be used within 45 days.
  • Child Safety: Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Cholestagel must be disposed of in accordance with local requirements. The medication should not be disposed of in household waste or via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cholestagel found in:

A-Z Index: